This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (10)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Social Bookmarking   What's this?

Graeme M. Lipper, MD; Kenneth A. Arndt, MD; Jeffrey S. Dover, MD, FRCPC

JAMA. 2000;283:175-177.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

INTRODUCTION

Recent advances in dermatologic therapy include the use of imiquimod beyond its original use as a treatment for anogenital condylomata acuminata. Another immunomodulating drug, tacrolimus, has been used topically to treat a variety of dermatoses. New concepts in the management of toxic epidermal necrolysis will also be discussed.

Imiquimod: Warts and Beyond

Imiquimod (Aldara, 3M Pharmaceuticals, St Paul, Minn), a novel immunomodulatory imidazoquinolin heterocyclic amine, has shown potent antiviral and antitumor action both experimentally and in recent clinical trials.^1-6 In clinical practice, the drug was approved by the Food and Drug Administration for topical application as a treatment of anogenital condylomata acuminata, and can be easily applied to affected areas by the patient at home, with 5% imiquimod cream left on overnight (6-10 hours) and then washed off, used 3 days a week for 16 weeks or until all visible warts . . . [Full Text of this Article]

Topical Tacrolimus as a Possible Dermatitis Treatment

Evolving Concepts in the Management of Toxic Epidermal Necrolysis (TEN)

Author Affiliations: Department of Dermatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Mass (Drs Lipper and Dover). Dr Arndt is a member of the JAMA Editorial Board and Editor of Archives of Dermatology.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

January 12, 2000
JAMA. 2000;283(2):273-274.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Analysis of Intravenous Immunoglobulin for the Treatment of Toxic Epidermal Necrolysis Using SCORTEN: The University of Miami Experience
Trent et al.
Arch Dermatol 2003;139:39-43.
ABSTRACT | FULL TEXT  

Allergy and Allergic Diseases- Second of Two Parts
Kay
NEJM 2001;344:109-113.
FULL TEXT